- Home
- SMID vs DMAC Comparison
SMID vs DMAC Comparison
Compare SMID & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMID
- DMAC
- Stock Information
- Founded
- SMID 1960
- DMAC 2000
- Country
- SMID United States
- DMAC United States
- Employees
- SMID N/A
- DMAC N/A
- Industry
- SMID Building Materials
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- SMID Industrials
- DMAC Health Care
- Exchange
- SMID Nasdaq
- DMAC Nasdaq
- Market Cap
- SMID 219.4M
- DMAC 310.1M
- IPO Year
- SMID 1995
- DMAC N/A
- Fundamental
- Price
- SMID $41.56
- DMAC $6.87
- Analyst Decision
- SMID
- DMAC Strong Buy
- Analyst Count
- SMID 0
- DMAC 3
- Target Price
- SMID N/A
- DMAC $12.33
- AVG Volume (30 Days)
- SMID 9.9K
- DMAC 448.5K
- Earning Date
- SMID 08-14-2025
- DMAC 11-12-2025
- Dividend Yield
- SMID N/A
- DMAC N/A
- EPS Growth
- SMID 162.25
- DMAC N/A
- EPS
- SMID 2.27
- DMAC N/A
- Revenue
- SMID $90,998,000.00
- DMAC N/A
- Revenue This Year
- SMID N/A
- DMAC N/A
- Revenue Next Year
- SMID N/A
- DMAC N/A
- P/E Ratio
- SMID $18.51
- DMAC N/A
- Revenue Growth
- SMID 32.97
- DMAC N/A
- 52 Week Low
- SMID $25.13
- DMAC $3.19
- 52 Week High
- SMID $51.96
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- SMID 53.89
- DMAC 63.84
- Support Level
- SMID $38.92
- DMAC $6.83
- Resistance Level
- SMID $41.81
- DMAC $7.41
- Average True Range (ATR)
- SMID 2.43
- DMAC 0.43
- MACD
- SMID -0.14
- DMAC 0.03
- Stochastic Oscillator
- SMID 76.89
- DMAC 73.62
About SMID Smith-Midland Corporation
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.